An update from the Foundation for Women's Cancer and Society of Gynecologic Oncology
Hear from Dr. Anil Sood, Foundation for Women's Cancer Research Chairman, and Carol Brown, 2014 Society of Gynecologic Oncology Program Chair, about research of interest to women and the public presented at the 2014 SGO Annual Meeting on Women's Cancer. (https://www.youtube.com/watch?v=KKB63TGlOcQ&feature=youtu.be)
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
October 1st 2023Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive
Cranbury, NJ 08512